Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC / Weimin Zhong, LiseGern, Thomas Stehle, Crisan Museteanu, Michael Kramer, Reinhard Wallich, and Markus M. Simon
Vaccination with outer surface protein A (OspA) of Borrelia burgdorferi prevents subsequent infection and disease in both laboratory animals and humans with high efficacy. OspA-based immunity, however, does not affect established infection due to the loss of OspA expression in the vertebrate host. We show here that repeated passive transfer of mouse and/or rabbit immune sera to recombinant GST-OspC fusion protein resulted in a dose-dependent resolution (1) of fully established arthritis and carditis as well as infection in needle-challenged C.B-17 SCID and (2) of infection in both experimentally and tick-infected BALB/c mice. Unexpectedly, active immunization of disease-susceptible AKR/N mice with GST-OspC only led to prevention but not resolution of disease and infection, in spite of high serum titers of OspC-specific Ab and the expression of ospC in tissue-derived spirochetes. The data suggest that the efficacy of OspC antibody-mediated immunity depends on the immunological history of the recipient and/or environment-dependent regulation of OspC surface expression by spirochetes in vivo. The results encourage further attempts to develop therapeutic vaccination protocols against Lyme disease..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
1999 |
---|---|
Erschienen: |
1999 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
European journal of immunology - 29(1999), 3, Seite 946-957 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhong, Weimin [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
First published: 28 March 2006 Gesehen am 17.02.2021 |
---|
Umfang: |
12 |
---|
doi: |
AID-IMMU946>3.0.CO;2-P |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1748527584 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1748527584 | ||
003 | DE-627 | ||
005 | 20230426072757.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210217s1999 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/(SICI)1521-4141(199903)29:03<946::AID-IMMU946>3.0.CO;2-P |2 doi | |
035 | |a (DE-627)1748527584 | ||
035 | |a (DE-599)KXP1748527584 | ||
035 | |a (OCoLC)1341393604 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Zhong, Weimin |e verfasserin |0 (DE-588)1227522894 |0 (DE-627)1748528653 |4 aut | |
245 | 1 | 0 | |a Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC |c Weimin Zhong, LiseGern, Thomas Stehle, Crisan Museteanu, Michael Kramer, Reinhard Wallich, and Markus M. Simon |
264 | 1 | |c 1999 | |
300 | |a 12 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a First published: 28 March 2006 | ||
500 | |a Gesehen am 17.02.2021 | ||
520 | |a Vaccination with outer surface protein A (OspA) of Borrelia burgdorferi prevents subsequent infection and disease in both laboratory animals and humans with high efficacy. OspA-based immunity, however, does not affect established infection due to the loss of OspA expression in the vertebrate host. We show here that repeated passive transfer of mouse and/or rabbit immune sera to recombinant GST-OspC fusion protein resulted in a dose-dependent resolution (1) of fully established arthritis and carditis as well as infection in needle-challenged C.B-17 SCID and (2) of infection in both experimentally and tick-infected BALB/c mice. Unexpectedly, active immunization of disease-susceptible AKR/N mice with GST-OspC only led to prevention but not resolution of disease and infection, in spite of high serum titers of OspC-specific Ab and the expression of ospC in tissue-derived spirochetes. The data suggest that the efficacy of OspC antibody-mediated immunity depends on the immunological history of the recipient and/or environment-dependent regulation of OspC surface expression by spirochetes in vivo. The results encourage further attempts to develop therapeutic vaccination protocols against Lyme disease. | ||
650 | 4 | |a Animals | |
650 | 4 | |a Antibodies, Bacterial | |
650 | 4 | |a Antigens, Bacterial | |
650 | 4 | |a Antigens, Surface | |
650 | 4 | |a Bacterial Outer Membrane Proteins | |
650 | 4 | |a Bacterial Vaccines | |
650 | 4 | |a Borrelia burgdorferi Group | |
650 | 4 | |a Disease Models, Animal | |
650 | 4 | |a Female | |
650 | 4 | |a Gene Expression | |
650 | 4 | |a Glutathione Transferase | |
650 | 4 | |a Immunization, Passive | |
650 | 4 | |a Kinetics | |
650 | 4 | |a Lipoproteins | |
650 | 4 | |a Lyme Disease | |
650 | 4 | |a Mice | |
650 | 4 | |a Mice, Inbred AKR | |
650 | 4 | |a Mice, Inbred BALB C | |
650 | 4 | |a Mice, SCID | |
650 | 4 | |a Rabbits | |
650 | 4 | |a Recombinant Fusion Proteins | |
650 | 4 | |a Ticks | |
650 | 4 | |a Vaccination | |
650 | 4 | |a Vaccines, Synthetic | |
700 | 1 | |a Gern, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Stehle, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Museteanu, Crisan |e verfasserin |4 aut | |
700 | 1 | |a Kramer, Michael D. |d 1958- |e verfasserin |0 (DE-588)172195608 |0 (DE-627)697109488 |0 (DE-576)133065863 |4 aut | |
700 | 1 | |a Wallich, Reinhard |e verfasserin |0 (DE-588)1059566710 |0 (DE-627)798640839 |0 (DE-576)163467781 |4 aut | |
700 | 1 | |a Simon, Markus M. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of immunology |d Weinheim : Wiley-VCH, 1971 |g 29(1999), 3, Seite 946-957 |h Online-Ressource |w (DE-627)302718842 |w (DE-600)1491907-2 |w (DE-576)079876684 |x 1521-4141 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:1999 |g number:3 |g pages:946-957 |g extent:12 |
856 | 4 | 0 | |u https://doi.org/0.1002/(SICI)1521-4141(199903)29:03<946::AID-IMMU946>3.0.CO;2-P |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_121 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_168 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_252 | ||
912 | |a GBV_ILN_266 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_647 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2036 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2043 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2158 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2193 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4277 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4328 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4346 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
912 | |a GBV_ILN_4753 | ||
936 | u | w | |d 29 |j 1999 |e 3 |h 946-957 |g 12 |
951 | |a AR | ||
952 | |d 29 |j 1999 |e 3 |h 946-957 |g 12 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3857000449 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 17-02-21 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd1999 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_7 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_12 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1546616403 |a Kramer, Michael D. | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416822720 |a Extern | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_4 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1485706335 |a Wallich, Reinhard | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416741488 |a Institut für Immunologie und Serologie | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_5 |